{
    "clinical_study": {
        "@rank": "60554", 
        "arm_group": [
            {
                "arm_group_label": "T80/A5/H12.5 mg FDC", 
                "arm_group_type": "Experimental", 
                "description": "A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet"
            }, 
            {
                "arm_group_label": "T80/A5 mg FDC+H12.5 mg mono", 
                "arm_group_type": "Active Comparator", 
                "description": "A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will be performed as an open-label, randomised, single-dose, two-sequence,\n      four-period replicated crossover design. A total of 72 Japanese healthy male subjects will\n      be randomised to 2 groups. The subjects are administrated either T80/A5/H12.5 mg FDC tablet\n      once or T80/A5 mg FDC tablet and hydrochlorothiazide (HCTZ) 12.5 mg tablet once in each\n      period. The length of admission will be 7 days in each period."
        }, 
        "brief_title": "Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy male subjects age =20 and =35 years; body weight: =50 kg and =80 kg; body\n             mass index: =18.0 and =25.0 kg/m2\n\n          -  Without any clinically significant findings and complications on the basis of a\n             complete medical history, including the physical examination, vital signs (blood\n             pressure (BP), pulse rate (PR), body temperature), 12-lead electrocardiograms (ECGs),\n             clinical laboratory tests\n\n          -  Signed and dated written informed consent prior to admission to the trial in\n             accordance with the Good Clinical Practice (GCP) and the local legislation.\n\n        Exclusion criteria:\n\n        - Any finding of the medical examination (including BP, PR and ECGs) deviating from normal\n        and of clinical relevance."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121535", 
            "org_study_id": "1348.3"
        }, 
        "intervention": [
            {
                "arm_group_label": "T80/A5/H12.5 mg FDC", 
                "intervention_name": "T80/A5 mg FDC tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T80/A5 mg FDC+H12.5 mg mono", 
                "description": "A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet", 
                "intervention_name": "T80/A5 mg FDC tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T80/A5/H12.5 mg FDC", 
                "intervention_name": "H12.5 mg tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T80/A5 mg FDC+H12.5 mg mono", 
                "description": "A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet", 
                "intervention_name": "T80/A5/H12.5 ng FDC tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T80/A5 mg FDC+H12.5 mg mono", 
                "description": "A  HCTZ 12.5 mg tablet", 
                "intervention_name": "H12.5 mf tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T80/A5/H12.5 mg FDC", 
                "intervention_name": "T80/A5/H12.5 mg FDC tablet", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Amlodipine", 
                "Telmisartan", 
                "Benzoates"
            ]
        }, 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanagawa, Yokohama", 
                    "country": "Japan"
                }, 
                "name": "1348.3.001 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Hydrochlorothiazide 12.5 mg Tablet in Healthy Male Subjects : an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum measured concentration (Cmax) of the analyte in plasma", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Area under the concentration-time curve (AUC 0-tz) of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121535"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the concentration-time curve (AUC 0-infinity) of the analyte in plasma over the time interval from 0 extrapolated to infinity", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}